| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H12N2O3S |
| Molecular Weight | 276.311 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(C=C1)S(=O)(=O)NC(=O)C2=CC=CC=C2
InChI
InChIKey=PBCZLFBEBARBBI-UHFFFAOYSA-N
InChI=1S/C13H12N2O3S/c14-11-6-8-12(9-7-11)19(17,18)15-13(16)10-4-2-1-3-5-10/h1-9H,14H2,(H,15,16)
| Molecular Formula | C13H12N2O3S |
| Molecular Weight | 276.311 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulfabenzamide is an antibacterial/antimicrobial. Often used in conjunction with sulfathiazole and sulfacetamide (trade name - Sultrin) as a topical, intravaginal antibacterial preparation against Haemophilus (Gardnerella) vaginalis bacteria. The mode of action of SULTRIN is not completely known. Indirect effects, such as lowering the vaginal pH, may be equally important mechanisms.
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Tox targets
Sourcing
PubMed
Patents
Sample Use Guides
The MTT assay was used to evaluate the viability of Epithelial tumor cell line, T-47D incubated with different concentrations of sulfabenzamide (0.0-20 mM). The 50% growth inhibition (LC50) concentration for sulfabenzamide after 48 h, were calculated as 10.8 mM. Cells incubated with sulfabenzamide exhibited negligible levels of apoptosis, necrosis and cell cycle arrest when compared to untreated cells. Despite negligible detection of DNA fragmentation, a considerable increase in caspase-3 activity was observed in cells incubated with sulfabenzamide.
line incubated with different concentrations of sulfabenzamide (0.0-20 mM) after 24, 48 and 72 h
